D
Douglas Brining
Researcher at National Institutes of Health
Publications - 14
Citations - 1272
Douglas Brining is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Ebola virus & Influenza A virus. The author has an hindex of 13, co-authored 14 publications receiving 1164 citations.
Papers
More filters
Journal ArticleDOI
Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques
Emmie de Wit,Angela L. Rasmussen,Darryl Falzarano,Trenton Bushmaker,Friederike Feldmann,Douglas Brining,Elizabeth R. Fischer,Cynthia Martellaro,Atsushi Okumura,Jean Chang,Dana P. Scott,Arndt Benecke,Arndt Benecke,Michael G. Katze,Heinz Feldmann,Vincent J. Munster +15 more
TL;DR: The MERS-CoV rhesus macaque model will be instrumental in developing and testing vaccine and treatment options for an emerging viral pathogen with pandemic potential and may explain the severity of the disease observed in humans and the limited human-to-human transmission.
Journal ArticleDOI
Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates
Andrea Marzi,Flora Engelmann,Friederike Feldmann,Kristen Haberthur,W. Lesley Shupert,Douglas Brining,Dana P. Scott,Thomas W. Geisbert,Yoshihiro Kawaoka,Michael G. Katze,Heinz Feldmann,Ilhem Messaoudi +11 more
TL;DR: It is suggested that antibodies play a critical role in rVSV-mediated protection against ZEBOV, and depletion of CD4+ T cells during vaccination caused a complete loss of glycoprotein-specific antibodies and abrogated vaccine protection.
Journal ArticleDOI
Protective Efficacy of Neutralizing Monoclonal Antibodies in a Nonhuman Primate Model of Ebola Hemorrhagic Fever
Andrea Marzi,Reiko Yoshida,Hiroko Miyamoto,Mari Ishijima,Yasuhiko Suzuki,Megumi Higuchi,Yukie Matsuyama,Manabu Igarashi,Eri Nakayama,Makoto Kuroda,Masayuki Saijo,Friederike Feldmann,Douglas Brining,Heinz Feldmann,Ayato Takada +14 more
TL;DR: The results indicate that EBOV neutralizing antibodies, particularly in combination with other therapeutic strategies, might be beneficial in reducing viral loads and prolonging disease progression during EHF.
Journal ArticleDOI
Clinical Outcome of Henipavirus Infection in Hamsters Is Determined by the Route and Dose of Infection
Barry Rockx,Douglas Brining,Joshua A. Kramer,Julie Callison,Hideki Ebihara,Keith G. Mansfield,Heinz Feldmann +6 more
TL;DR: Novel information is revealed on the development and progression of NiV and HeV clinical disease, a mechanism for the differences in transmission observed between NiV or HeV outbreaks is provided, and specific cytokines and chemokines that serve as important targets for treatment are identified.
Journal ArticleDOI
A Novel Model of Lethal Hendra Virus Infection in African Green Monkeys and the Effectiveness of Ribavirin Treatment
Barry Rockx,Katharine N. Bossart,Friederike Feldmann,Joan B. Geisbert,Andrew C. Hickey,Douglas Brining,Julie Callison,David Safronetz,Andrea Marzi,Lisa Kercher,Dan Long,Christopher C. Broder,Heinz Feldmann,Thomas W. Geisbert +13 more
TL;DR: This work examines the pathogenesis of HeV in the African green monkey (AGM) following intratracheal inoculation and examines the antiviral effect of ribavirin in a cohort of nine AGMs before or after exposure to HeV, demonstrating that, while Ribavirin may have some antiviral activity against the henipaviruses, its use as an effective standalone therapy for HeV infection is questionable.